论文部分内容阅读
【目的】回顾性研究慢性HBV感染者经长期核苷(酸)类似物治疗获得HBs Ag阴转停药后疗效的持久性。【方法】对28例使用核苷(酸)类似物总疗程≥24月,获得HBs Ag阴转的慢性HBV感染者,予以停用核苷(酸)类似物治疗后进行肝脏生化学、病毒学、血清学检测和随访观察。【结果】28例服用核苷(酸)类似物获得HBs Ag阴转停药的慢性HBV感染者经过平均2.3(0.8~7.5)年的停药观察,无一例患者复发。停药时(n=28)、停药后24周(n=28)、48周(n=24)、72周(n=23)、96周(n=18)ALT复常率分别为:77.8%、77.8%、87.5%、84.6%、100%;HBV DNA不可测率、HBe Ag阴转率、HBe Ag/HBe Ab转换率及HBs Ag阴转率各时间点全部为100%;HBs Ag/HBs Ab转换率各时间点分别为:42.9%、42.9%、42.3%、52.2%、61.1%。28例患者无一例患者出现生化学、病毒学突破及肝炎复发。【结论】慢性HBV感染者经长期核苷(酸)类似物治疗获得HBs Ag阴转停药后疗效持久、无复发。
[Objective] To retrospectively study the persistence of curative effect of long-term nucleotide (acid) analogue therapy for HBsAg-negative patients after chronic HBV infection. 【Methods】 Twenty-eight patients with chronic HBV infection who were treated with nucleos (s) acid analogues for 24 months or longer with negative HBsAg were treated with nucleoside (acid) analogues for liver biochemistry and virology , Serological test and follow-up observation. 【Results】 28 patients with chronic HBV infection who received nucleos (s) analogues as HBsAg-negative drug withdrawal experienced an average of 2.3 (0.8-7.5) years of withdrawal, and none of the patients relapsed. The rates of ALT abnormalities at discontinuation (n = 28), 24 weeks (n = 28), 48 weeks (n = 24), 72 weeks (n = 23), and 96 weeks (n = 18) 77.8%, 77.8%, 87.5%, 84.6% and 100%, respectively; all the time points of HBV DNA undetectable rate, HBe Ag negative conversion rate, HBe Ag / HBe Ab conversion rate and HBs Ag negative conversion rate were 100% / HBs Ab conversion rate at each time point were: 42.9%, 42.9%, 42.3%, 52.2%, 61.1%. None of the 28 patients presented with biochemical, virologic breakthrough and hepatitis recurrence. 【Conclusion】 Long-term nucleotide (acid) analogue treatment of patients with chronic HBV infection obtained long-term HBsAg-negative drug withdrawal without relapse.